Regulation of Angiogenesis in Choroidal Neovascularization of Age Related Macular Degeneration by Endogenous Angioinhibitors

Venugopal Gunda¹ and Yakkanti A. Sudhakar¹,²
¹Cell Signaling, Retinal and Tumor Angiogenesis Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE, ²Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

1. Introduction

The sense of vision has utmost significance and the loss of vision leads to the impairment of active human behavior as evident in pathological disorders that affect vision. Among different pathological visual disorders, Age Related Macular Degeneration (AMD/ARMD) is of serious concern as a leading cause of blindness, observed with aging globally. The clinical manifestation of AMD includes retinal damage with the degeneration of macula, leading to the partial or complete loss of acuity in vision. One form of pathologic AMD named, “wet form of AMD”, involves the growth of new blood vessels from the choroid which lies underneath the retina, leading to the pathological blood vessel growth termed as Choroidal Neovascularization (CNV), with subsequent damage to the retina. Thus, choroidal neovascularization reflects a pathological angiogenic condition, where the loss of regulation over angiogenesis leads to the retinal damage. It also indicates that, the regulation of pathological angiogenesis can be an efficient strategy in preventing CNV of AMD. Though, some genetic disposition and aging factors are identified as peculiar etiological factors causing AMD; recent studies have shown that different cellular mechanisms regulating angiogenesis are common in different angiogenic scenarios including CNV. Further, the role of different endogenous angiogenesis inhibitors/angioinhibitors conferring the tissues with angiogenic regulation has been deciphered, which can be applied for regulation of CNV in AMD through inhibition of angiogenic signaling mechanisms. The present chapter provides an overview of the role of factors leading to choroidal neovascularization, the mechanisms underlying such angiogenesis and also the scope for endogenous angioinhibitors in regulation of CNV of AMD.

1.1 Retina and choroid

Retina is the inner most layer of the eye, which possesses anatomically ten distinct layers that are broadly categorized into two layers. The inner neural layer comprising of extensive
nervous tissue towards the vitreous chamber and the outer retinal pigmented epithelium (RPE) adhering to the choroid. Some of the functions of the RPE include the phagocytosis of outer retinal segmental discs, maintenance of chorio-capillaries, fluid and electrolyte balance in subretinal space. Choroid is the highly vascular and pigmented tissue of the eye lying between the retina and the sclera. It consists of lamina suprachoroidea adhering to sclera, followed by lamina vesculos, chorio-capillaries, stroma and Bruch membrane adhering to the RPE. Choroid is rich in vasculature and the extracellular matrix (ECM) components, including collagen and elastin fibers. It provides nutrient, metabolite and gaseous exchange to the retina by diffusion through chorio-capillaries.

1.2 Choroidal neovascularization in age related macular degeneration

The histological proximity between retinal pigmented epithelium and choroid confers not only physiological but also pathological effect on RPE. The mechanical barrier that separates the RPE from choroid is the Bruch membrane, which in turn consists of basement membrane secreted by RPE, inner collagenous layer, elastic layer, outer collagenous zone and the basement membrane of chorio-capillaries acting as a mechanical barrier for the underlying chorio-capillaries, but facilitating diffusion of metabolites and gaseous exchange for RPE. In cases of CNV the Bruch membrane is distorted with initial deposition of lipid and proteinaceous component called ‘drusen’ followed by the growth and penetration of blood capillaries from choroid into Bruch membrane, finally leading to the leakage of fluid into sub-retinal spaces and retinal or retinal pigmented epithelial damage (Green, 1999; Green and Enger, 1993; Jager et al., 2008).

1.3 Factors for choroidal neovascularization in age related macular degeneration

Pathological neovascularization in CNV of AMD is considered to be contributed by both the angiogenesis and vasculogenesis, which are the processes of de-novo blood vessel formation (Chan-Ling et al., 2011; Jager et al., 2008). Angiogenesis is the process of formation of new blood vessels from the pre-existing ones, which involves the role of different cell types and remodeling of ECM. The inception of different cell types involved in the angiogenesis, such as, the endothelial cells (ECs) of RPE and choroid involved in CNV, mural cells and inflammatory cells occurs through vasculogenesis, by the differentiation of endothelial progenitor cells (EPCs). The EPCs found in the normal circulation are recruited into angiogenic sites, where they differentiate into different cell types leading to angiogenesis (Chan-Ling et al., 2011; Jager et al., 2008). However, the salient feature of neovascularization involves the common sequential events of angiogenesis including the proliferation of ECs, degradation of ECM or vascular basement membrane (VBM) by ECs through secretion of proteases, migration and differentiation of ECs into tip and stalk cells, lumen development, ECM reorganization and finally vessel anastomosing into functional capillaries (Carmeliet and Jain, 2000). These sequential steps of angiogenesis are considered to be common for CNV, which are initiated by the release of angiogenic factors by the RPE and other cell types differentiated from EPCs or infiltrating through the leaky capillaries in response to aging evoked stress (Alon et al., 1995; Grossniklaus et al., 2002). The initiating cellular and physiological factors that lead to the secretion of angiogenic factors by ECs and other cell types have been identified in different studies, which can be systematically framed for synergistic interpretation of etiological factors leading to CNV.
The normal function of phagocytosis and degradation of phagocytosed membranes is impaired with aging in RPE, leading to the accumulation of lipofuscin in these cells, with senescence (Marshall, 1987; Young and Bok, 1969). Ischemia and hypoxia evident in the ocular tissues of CNV are identified as factors promoting free radical generation in RPE and also the release of cellular lipids and proteinaceous deposits into the Bruch membrane (Spaide et al., 2003). Thus, impairing Bruch membrane’s barrier function and in turn leading to the secretion of different angiogenic factors like vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), basic fibroblast growth factor (bFGF), insulin-like growth factor-1 and platelet derived growth factor (PDGF) by the RPE and the macrophages and stromal cells that are recruited by the differentiation of EPCs (Alon et al., 1995; Grossniklaus et al., 2002; Lu and Adamis, 2006; Penn et al., 2008; Young and Bok, 1969). Damage to the Bruch membrane is considered to enhance the diffusion of the growth factors, which elicit angiogenic signaling in the ECs (Lu and Adamis, 2006; Marshall, 1987; Penn et al., 2008).

Fig. 1. The angiogenic balance between endogenous angioactivators and angioinhibitors regulate vascular homeostasis. Angiogenesis under physiological and pathological conditions is associated with up-regulation of endogenous angioactivators and/or down-regulation of endogenous angioinhibitors. Up-regulation of angioinhibitors and/or down-regulation of angioactivators may be associated with impaired neovascularization capacity in the choroidal neovascularization in age related macular degeneration (CNV of AMD). VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; IGF-I, insulin-like growth factor-I; IL-8, interleukin-8; PDGF, platelet-derived growth factor; PlGF, placental growth factor; TGF-α and β, transforming growth factor-α and β; HGF, Hepatocyte growth factor.
Table 1. Endogenous activators, their receptors and angiogenic activities (EC: endothelial cell, ECM: extracellular matrix, FGFRs: Fibroblast growth factor receptors, Flk-1: Fetal liver kinase-1, Flt-1, 4: fms-related tyrosine kinase, GPCRs: G-protein coupled receptors, HSPG: Heparan sulfate proteoglycan, KDR: kinase insert domain receptor, MMP: matrix metalloproteinase, NO: nitric oxide, Pak: p21 protein activated kinase, PDGF: platelet derived growth factor, Tie: tyrosine kinase with immunoglobulin-like and EGF-like domains, VEGFRs: vascular endothelial growth factor receptors)

<table>
<thead>
<tr>
<th>Endogenous Angioactivators</th>
<th>Potent Receptors</th>
<th>Angiogenic action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular endothelial growth factor (VEGF) &amp; Placental growth factor (PIGF)</td>
<td>VEGFRs (Flt-1, Flk-1, KDR, Flt-4), Neuropilins, HSPG, integrins</td>
<td>Increases EC permeability, proliferation, migration, NO, uPA/PAI-1 &amp; MMP production. Inhibiting EC apoptosis. Promotes ECM degradation. Monocyte migration.</td>
</tr>
<tr>
<td>Transforming growth factor-β (TGF-α, β)</td>
<td>Transforming growth factor receptors</td>
<td>Increased vessel stability and organization, promote secretion of ECM components.</td>
</tr>
<tr>
<td>basic Fibroblast growth factor (bFGF)</td>
<td>FGFRs, HSPG, integrins</td>
<td>Promotes EC proliferation, migration, tube formation, ECM degradation, vessel maturation.</td>
</tr>
<tr>
<td>Insulin-like growth factor-1 (IGF-1)</td>
<td>Insulin-like growth factor receptors</td>
<td>Promotes EC migration, proliferation, tube formation.</td>
</tr>
<tr>
<td>Platelet derived growth factor (PDGF)</td>
<td>PDGF-α, β, GPCRs, integrins</td>
<td>Increases EC permeability, proliferation, migration.</td>
</tr>
<tr>
<td>Angiopoietin-1</td>
<td>Tie-2, integrins</td>
<td>EC sprouting, Vessel stabilization.</td>
</tr>
<tr>
<td>Hepatocyte growth factor (HGF)</td>
<td>Hepatocyte growth factor receptor</td>
<td>Promotes tubulogenesis along with other factors.</td>
</tr>
<tr>
<td>Interleukin-8 (IL-8)</td>
<td>C-X-C chemokine receptor type (CXCR-1,2)</td>
<td>Activates neovascularization increasing invasiveness of different cell types.</td>
</tr>
<tr>
<td>Matrix metalloproteinases (MMPs)</td>
<td></td>
<td>Degradation of ECM components promoting EC migration and vessel organization, release of ECM or cell surface bound/sequestred angiogenic factors.</td>
</tr>
</tbody>
</table>

The integrins and other ECM binding receptors present on ECs are essential in maintaining the ECM promoted survival and migration in angiogenesis (Avraamides et al., 2008; Mettouchi and Meneguzzi, 2006). The synergistic activation of integrins and other ECM binding receptors on ECs by the growth factors and cytokines leads to the activation of different signaling cascades mediated by the kinases, secondary messengers, transcription factors such as, nuclear factor kappa β (NF-κβ), hypoxia inducible factor-1α (HIF-1α), and other enzymes such as, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and metalloproteinases (MMPs) (Avraamides et al., 2008; Boosani et al., 2007; Egeblad and Werb, 2002; Mettouchi and Meneguzzi, 2006; Oklu et al., 2010). The transcription factors that are stabilized, up-regulated or expressed under hypoxia also lead to activation of different signaling cascades that promote effective survival and proliferation of ECs. The secretion of proteases such as matrix metalloproteinases (MMPs) including collagenases and elastases, which degrade the collagen and elastin of vascular basement membrane (VBM) promote the migration of ECs. The urokinase is another protease, which binds to its receptors (urikase binding receptor, uPAR) and activates signaling cascades leading to the secretion of MMPs, which promote migration of ECs and angiogenesis. The organization and differentiation of...
migrating ECs into tip and stalk cells is further enumerated to be regulated by Wingless type (Wnt)/Frizzled-Notch signaling that provides an insight about formation of functional capillaries in neovascular vessels (Dejana, 2010; Zerlin et al., 2008).

The inflammatory cells that are recruited through the expression of cytokines such as monocyte chemo-attractant protein-1 (CCL2/MCP-1), Chemokine (C-X-C motif) ligand 1 (CXCL1), macrophage inflammatory protein-1/-2 (MIP-1, MIP-2) are also considered to play role in CNV progression (Hendricks, 2006). Further, the intriguing stimulative role of Bruch membrane in promoting AMD is also being deciphered by identifying the complement components 3a and 5a (C3a and C5a), which lead to the up-regulation of VEGF-A (Nozaki et al., 2006). Thus, the orchestration of various signaling events at different stages of angiogenesis leads to the neovascularization. The angiogenic ECs lining the neovascular vessels arising due to the above factors in CNV are found to possess fenestrations and also organize into defective capillaries leading to the leakage of macromolecules as well as vascular cells into the Bruch membrane and sub-retinal spaces leading to the degeneration of macula of retina (Dvorak et al., 1995; Roberts and Palade, 1995).

2. Endogenous angioinhibitors

In addition to the angiogenic factors, which activate angiogenesis, tissues and ECM also possess angioinhibitors, which have the potency to inhibit the angiogenesis and thus, regulating the pathological angiogenesis by inhibiting the signaling mechanisms activated by angiogenic factors (Boosani et al., 2010; Sudhakar and Kalluri, 2010, Zhang and Ma, 2007). Nearly, 40 endogenous angioinhibitors have been characterized and some of them are found in the ocular tissues or secreted into vasculature and released into ocular tissues, where they exhibit angio-inhibition and finally regulation of CNV (Boosani et al., 2011; Sudhakar and Kalluri, 2010). The significance of imbalance in the levels of endogenous angioinhibitors and angioactivators in regulation of vascular homeostasis can be summarized as in Figure 1. This significance was also ascertained by the evaluations showing the correlation between the decrease in specific angioinhibitors and the progression of CNV (Bhutto et al., 2008).

2.1 Mechanisms of regulation of CNV by endogenous angioinhibitors

2.1.1 Vasoinhibins

The vasoinhibins (14-18 kDa) are antiangiogenic peptides found in the pituitary, retina and extrapituitary tissues. They constitute the amino terminal regions of three different precursors; prolactin, growth hormone and placental lactogen. Though their precursors do not exhibit angioinhibitory activities; vasoinhibins found in the tissues or those expressed using recombinant methods exhibit antiangiogenic properties (Clapp et al., 2008). The therapeutic potential of vasoinhibins in regulating angiogenesis in CNV and tumor growth was evaluated and studies indicate that adenovirus mediated expression of vasoinhibins inhibits CNV, in-vivo and also angiogenesis (Zhou et al., 2010). Mechanisms of regulation of EC survival, proliferation and migration by the vasoinhibins have been deciphered in different studies; nevertheless, the receptors through which the mechanisms are mediated still remain enigmatic. Vasoinhibins regulate the EC migration and survival through inhibition of VEGF and bFGF stimulated MAPK activation (D’Angelo et al., 1995).
<table>
<thead>
<tr>
<th>Endogenous Angioinhibitor</th>
<th>Parent molecule</th>
<th>Receptors</th>
<th>Mode of action/ Inhibition pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasoinhibins</td>
<td>Prolactin, growth hormone</td>
<td>Not known</td>
<td>Sos/Ras/MAPK or eNOS /Raf/MAPK, Ca2+ / eNOS/protein phosphatase 2, Ras/Tiam-1/Rac1/Pak1, Bcl-XL, NF-kβ, caspases</td>
</tr>
<tr>
<td>PEDF</td>
<td>PEDF</td>
<td>Not known</td>
<td>Possible apoptosis</td>
</tr>
<tr>
<td>Arresten</td>
<td>Collagen IV, α1 NC1</td>
<td>αVβ3, αVβ5 integrins, Fas</td>
<td>Raf/MEK/ERK1/2/p38-MAPK, HIF-1α, MMPs</td>
</tr>
<tr>
<td>Canstatin</td>
<td>Collagen IV, α2 NC1</td>
<td>αβ1 integrin, HSPG</td>
<td>proapoptosis-8 and -9, Akt/ FAK/mToR, elf-4EBP-1, Ribosomal S6-kinase</td>
</tr>
<tr>
<td>Turnstatin</td>
<td>Collagen IV, α3NC1</td>
<td>CD47/IAP, αVβ3, α6β1 integrins</td>
<td>FAK/Akt/PI3K/mTOR/ elf-4EBP1/NFκB, COX-2 signaling</td>
</tr>
<tr>
<td>Endostatin</td>
<td>Collagen XVIII-NC1</td>
<td>αVβ3/α5β1 integrins, HSP, glypican, caveolin-1</td>
<td>Ras/Raf/KDR/Flk-1 / ERK/p38-MAPK/p125 FAK/HIF1α/Ephrin/TNFα/NFκB, Wnt signaling</td>
</tr>
<tr>
<td>Angiostatin</td>
<td>Plasminogen</td>
<td>ATP synthases, αVβ3 integrin, angiostatin</td>
<td>αVβ3 integrin mediated apoptosis, ATP synthase</td>
</tr>
<tr>
<td>Thrombospondins</td>
<td>TSP</td>
<td>CD36, IAP, CD47, HSPG, α3β1 , other integrins</td>
<td>Src-family kinases/ Caspase-3/p38 MAPK, TGF-β signaling</td>
</tr>
<tr>
<td>Endorepellin</td>
<td>Perlecan</td>
<td>α2β1 integrins, lipid rafts, caveolin</td>
<td>cAMP-PKA/FAK/p38-MAPK/Hsp27, SHP-1, Ca2+ signaling</td>
</tr>
</tbody>
</table>

VEGF activated Sos/Ras/MAPK or eNOS/Raf/MAPK-mediated proliferative signaling and Ca2+/eNOS/protein phosphatase-2 mediated vascular permeability and vasodilatation were shown to be inhibited by the vasoinhibins (Gonzalez et al., 2004; Ziche and Morbidelli, 2000). In addition vasoinhibins also inhibit the migration of EC stimulated by IL-1β through Ras/Tiam-1/Rac-1/Pak1 and promote apoptosis through conversion of Bcl-XL to proapoptotic Bcl-Xs and NF-κB mediated activation of initiator and effector caspases (Martini et al., 2000; Tabruyn et al., 2003).

### 2.1.2 Pigment Epithelium Derived Factor (PEDF)

Pigment epithelium derived factor (PEDF) is a 50 kDa, secreted, serpin family glycoprotein, first identified from the cultured fetal RPE conditioned media (Tombran-Tink et al., 1991). PEDF accumulates in the vitreous humor and is also expressed in different adult tissues (Tombran-Tink et al., 1991). Addition of PEDF to the cultured HUVECs increased the number of TUNEL positive cells suggesting apoptotic mode of action of PEDF and thus, possibly preventing EC response to ischemia in-vivo (Ho et al., 2007). The levels of PEDF were found to be decreased in Bruch membrane with progression of AMD and concomitant increase in VEGF levels were also identified with decrease in PEDF levels (Bhutto et al., 2008). Different methods of PEDF upregulation have been applied to investigate the effect of PEDF on CNV. Intravitreous injections of adenovirus expressing the PEDF and ultrasound-microbubble technique of noninvasive gene transfer of PEDF gene in rats exhibited significant decrease in the CNV (Gehlbach et al., 2003; Zhou et al., 2009). However, studies also demonstrate that PEDF at lower doses (90 μg/ml) has negative effect on CNV whereas; higher doses (2-4 fold) can augment CNV; thus, indicating a strategic approach to be developed during clinical trials for CNV treatment with PEDF (Apte et al., 2004).

### 2.1.3 Angiostatin

Angiostatins are 38-45 kDa kringle domains derived by the protease activity of parent molecule plasminogen, which itself has significant role in activation of fibrinogen and blood clotting (Hayashi et al., 2008). Some of the angiostatin peptide derivate exhibit anti-angiogenic properties including inhibition of EC proliferation, tube formation and migration. The application of angiostatins in regulating CNV of AMD was evaluated by the expression of the angiostatins in-vivo, using viral vectors (Lai et al., 2001). Angiostatins bind to ATP synthases on the surface of ECs leading to their apoptotic death (Burwick et al., 2005; Tarui et al., 2001). Further αVβ3 integrin and angiomotin are also shown to bind angiostatin and induce apoptosis (Burwick et al., 2005; Tarui et al., 2001).

### 2.1.4 Thrombospondins

Thrombospondins (TSPs) are secreted ECM glycoproteins playing key role in the cellular and ECM interactions (Bornstein, 2001; Lawler, 2000). The NH2-terminal peptides derived from the TSPs, by the action of different proteases are identified to possess angioinhibitory properties. TSP-1 and TSP-2 are trimeric globular domain subunits (145 kDa) categorized into subgroup-A and subgroup-B consists of TSP’s 3-5, which are pentameric subunits (110 kDa) (Bornstein, 2009). TSP-1 was the first identified ECM derived endogenous
angioinhibitor from many normal tissues and produced by a variety of cells including platelets, megakaryocytes, epithelial, endothelial and stromal cells (Bornstein, 2009). TSP-1 is secreted by the retinal-pigmented epithelium (RPE) and regulates angiogenesis in normal eye (Miyajima-Uchida et al., 2000). Immunolocalization studies showed decrease in the levels of TSP in the chorio-capillaries and the Bruch membrane of AMD samples (Bhutto et al., 2008). Wispostatin-1 (WISP-1) repeat derived peptide from TSP-1 was shown to inhibit the CNV in LASER induced CNV mice models (Cano Medel et al., 2009). TSP-1 induces apoptosis in ECs through CD36 and integrin associated protein (IAP)/Src-family protein kinases/Caspase-3/p38 MAPK signaling (Dawson et al., 1997). In addition TSP-1 can also bind to different integrins, including CD47 and heparin sulfated proteoglycans (Kaur et al., 2011). Thus the significance of TSPs in regulation of CNV have been evaluated through detection of endogenous levels in pathological tissues and also by evaluating the effects of TSPs both in vitro and in vivo.

2.1.5 Arresten

Arresten [α1(IV)NC1], is the 26 kDa collagen type IV, α1 chain derived non-collagenous domain, which functions via binding to α1β1 integrin and heparan sulfate proteoglycans, regulating bFGF and VEGF stimulated activation of ECs (Boosani and Sudhakar, 2006; Colorado et al., 2000; Sudhakar et al., 2005). It inhibits the survival of mouse lung endothelial cells through inhibition of FAK phosphorylation in AKT independent manner (Sudhakar et al., 2005). FAK inhibition by arresten via α1β1 integrin leads to inhibition of downstream Raf/MEK/ERK1/2/p38 MAPK signaling and HIF-1α expression (Figure 2). Inhibition of HIF-1α by arresten is critical in preventing hypoxic survival of ECs through VEGF regulation (Sudhakar et al., 2005). Arresten inhibited VEGF-mediated angiogenesis by promoting apoptosis, caspase-3/PARP activation and negatively impacting FAK/p38-MAPK phosphorylation, Bcl-2 and Bcl-xL expressions leading to mouse retinal endothelial cell (MREC) death (Boosani et al., 2009). In addition angioinhibitory activity of arresten was found to inhibit bFGF induced proliferation of MREC in-vitro in a dose dependent manner. It also inhibited the bFGF-induced migration of MREC mediated by MMP-2 activity but not the expression levels of MMP-2 (Boosani et al., 2010). Thus, arresten was shown to effect the proliferation and migration of choroidal endothelial cells and regulate CNV of AMD. The endothelial specific inhibitory actions of arresten may be of benefit in the treatment of a variety of eye diseases with a neovascular component.

2.1.6 Canstatin

It is the 24 kDa collagen type IV, α2 derived non-collagenous domain [α2(IV)NC1], which binds to the αVβ3 and αVβ5 integrins and inhibits EC proliferation, migration and tube formation by enhancing apoptosis in these cells (Magnon et al., 2005; Magnon et al., 2007; Petitclerc et al., 2000; Roth et al., 2005). The antiangiogenic efficacy of canstatin in regulating the neovascularization of cornea was also evaluated using the recombinant canstatin in alkali burn induced neovascularization study (Lima et al., 2006; Wang et al., 2011). Canstatin was shown to induce apoptosis through the induction of Fas-ligand, activation of procaspase-8 and -9 cleavage, reduction in membrane potential, inhibition of Akt, FAK, mToR, eIF-4E/4E-BP1 and ribosomal S6-kinase phosphorylations, in cultured HUVECs (Figure 2) (Panka and Mier, 2003).
Fig. 2. **Schematic illustration of distinct angioinhibitory signaling mediated by different extracellular matrix (ECM) reloaded molecules.** Tumstatin, arresten, canstatin and endostatin interact with $\alpha V\beta 3/\alpha 3\beta 1$, $\alpha 1\beta 1$, $\alpha V\beta 3/\alpha V\beta 5$ and $\alpha 5\beta 1$ integrins respectively, to inhibit the phosphorylation of focal adhesion kinase (FAK). Tumstatin: It binds to $\alpha V\beta 3$ and $\alpha 3\beta 1$ integrins and inhibits the pathway that includes phosphorylation of FAK, PI3-K, Akt, mTOR, 4E-BP1 and eIF4E to decrease endothelial cell protein synthesis and proliferation. In addition tumstatin also inhibits NFκB mediated signaling in hypoxic conditions leading to inhibition of COX-2, VEGF and bFGF expressions, resulting in inhibition of hypoxic tumor angiogenesis. Arresten: It binds to $\alpha 1\beta 1$ integrin and inhibit phosphorylation FAK, causes inhibition of Ras, Raf, extra cellular signal related kinase 1 (ERK1) and p38 MAPK pathways that leads to inhibition of HIF-1$\alpha$ and VEGF expression resulting in inhibition of endothelial cell migration, proliferation and tube formation. In addition arresten initiates two apoptotic pathways, involving activation of caspase-9 and -8, leading to activation of caspase-3 and PARP cleavage. (a) Arresten activates caspase-3 directly through inhibition of FAK/p38-MAPK/Bcl-2/Bcl-xl, and activation of caspase-9; (b) Integrin $\alpha 1\beta 1$ cross talk with Fas-L through mitochondrial pathway and leads to activation of caspase-8 and-3 in
proliferating endothelial cells. Canstatin: It binds to $\alpha V\beta 3/\alpha V\beta 5$ integrins and inhibits two apoptotic pathways, involving activation of caspase-8 and caspase-9, leading to activation of caspase-3. Canstatin activates procaspase-9 not only through inhibition of the FAK/PI3K/AKT pathways but also by integrins cross talking mitochondrial pathway through Fas-L dependent caspase-8 activation leads to endothelial cell apoptosis. CM represents cell membrane. Endostatin: It binds to $\alpha 5\beta 1$ integrin and inhibit phosphorylation FAK, causes inhibition of Ras, Raf, extra cellular signal related kinase-1 (ERK1) and p38 MAPK pathways that leads to inhibition of endothelial cell migration and tube formation.

2.1.7 Tumstatin

Tumstatin [$\alpha 3$(IV)NC1], is a 28 kDa collagen type IV, $\alpha 3$ chain derived non-collagenous domain with anti-angiogenic and proapoptotic activities. It binds to the CD47/IAP, $\alpha V\beta 3$, $\alpha 3\beta 1$ and $\alpha 6\beta 1$ integrins and inhibits the signaling cascade mediated by FAK, Akt, PI3K/mTOR/elf-4E/4E-BP1 and NFkB/COX-2 (Boosani et al., 2007; Hamano et al., 2003; Maeshima et al., 2002; Monboisse et al., 1994; Sudhakar et al., 2003). Inhibition of elf-4E/4E-BP1 by tumstatin leads to the regulation of cap dependent translational level of genes, whereas inhibition of transcriptional factor signaling such as NFkB leads to regulation of genes such as COX-2 at transcriptional level (Figure 2) (Boosani et al., 2007). Thus, tumstatin exhibits gene regulation in endothelial cell-specific and integrin-dependent manner. Angioinhibitory effect of tumstatin has been evaluated in regulation of CNV in mice (Boosani et al., 2011). Recombinant tumstatin regulated tube formation by mouse corneal endothelial cells (MCECs) in-vitro and adeno viral mediated expression of tumstatin in-vivo in mice has shown reduction in CNV (Boosani et al., 2011; Gunda et al., 2011).

2.1.8 Endostatin

Endostatin is the partial 20-kDa fragment of collagen type XVIII, carboxy terminal non-collagenous domain, derived from the parent collagen by proteolytic cleavage activities of elastase and cathepsin-L (Felbor et al., 2000). Endostatin is found in normal circulation enabling it to be utilized as an effective angioinhibitor without toxic effects (Fukai et al., 2002). Lower levels of endostatin have been recorded in CNV samples compared to the healthy donor eyes and within the tissues of progressive AMD (Bhutto et al., 2008; Fukai et al., 2002). Deletion of endostatin or collagen type XVIII massively up-regulates LASER induced CNV; where as administration of physiological concentrations of endostatin was able to inhibit such CNV in these mice (Marneros et al., 2007). Endostatin also down regulates the expression of VEGF in experimental CNV rat models (Takahashi et al., 2003). These observations along with the evidence of inhibition of CNV with intravenous injection of adenoviral vectors that express secretable endostatin, confirm the significance of endostatin in regulation of CNV (Mori et al., 2001; Wickstrom et al., 2003).

Endostatin elicits the anti-proliferative and anti-migratory effects by binding to different EC surface molecules and regulating the signaling cascades (Faye et al., 2009). Recombinant endostatin binds to $\alpha V$ integrin as shown in human endothelial cells (Rehn et al., 2001). Further studies have also shown localization of endostatin in the lipid rafts and association with caveolae (Wickstrom et al., 2002; Wickstrom et al., 2003). Surface plasmon resonance assays characterized the binding of endostatin to both $\alpha V\beta 1$ integrins and the heparin
sulfates and also localization to the lipid rafts (Ricard-Blum et al., 2004). In-vitro assays using ECs also showed the co-localization of endostatin with α5β1 integrin, actin stress fibers, membrane anchor protein and caveolin-1, which enumerates the interaction of endostatin with caveolae, inhibiting EC migration through the disassembly of actin stress fibers/focal adhesions, activation of Src and impaired fibronectin deposition by ECs in response to bFGF (Wickstrom et al., 2002; Wickstrom et al., 2003; Sudhakar et al., 2003). Binding of endostatin with integrins also down-regulates the activity of RhoA-GTPase and inhibits signaling pathways mediated by small kinases of the Ras and Raf families (Ricard-Blum et al., 2004). In addition, binding to the KDR/Flk-1, endostatin inhibits the VEGF-induced tyrosine phosphorylation of KDR/Flk-1 and activation of ERK, p38 MAPK, and p125FAK in HUVECs (Kim et al., 2002; Sudhakar et al., 2003). Further signaling cascades regulated by the endostatin are being identified, which are mediated by activator protein 1 (Id), HIF1α, ephrin, tumor necrosis factor-α (TNFα), nuclear factor-κB (NFκB), coagulation cascades, adhesion molecules and Wnt, which indicate the potential role of endostatin as an endogenous angioinhibitor (Nyberg et al., 2005) (Figure 2).

2.2 Scope for endogenous angioinhibitors in CNV treatment

Current modalities of treatment for the CNV in AMD include the regulation of angiogenesis as angiogenesis being one of the pathological factors of neovascularization. The therapies such as LASER photocoagulation, photodynamic therapy and anti-VEGF therapies using Macugen or Lucentis, that are currently being applied to regulate the CNV have their own constraints such as development of lesions, loss of acuity in vision and frequent administration, respectively (Gallemore and Boyer, 2006). Alternative strategies for the treatment of CNV in AMD are therefore being developed in which the specific targeting on angiogenesis can be possible. Endogenous angioinhibitors are considered as one of the area to be explored in this arena to include them in regimens of complementary treatments for the regulation of CNV (Chappelow and Kaiser, 2008; Do, 2009). The signaling cascades regulated by some of endogenous angioinhibitors have been identified (Table 2 and Figure 2), which enabled the application of those inhibitors in CNV.

3. Conclusions

The cellular, extracellular milieu and genetic factors responsible for the neovascularization arising in AMD are being deciphered with emphasis on identifying those factors that play a key role in the inception and progression of CNV. In this scenario, different etiological factors have been identified which regulate angiogenesis, effecting both extracellular milieu and intracellular angiogenic signaling pathways. Identification of the signaling cascades leading to the pathological angiogenesis in CNV has further lead to the possibility of regulating CNV, by focusing on signaling pathways as one of the targets. Application of endogenous angioinhibitors has proven as a promising strategy in this scenario of inhibiting angiogenic pathways that are identified in CNV. The inhibitors such as vasoinhibins, PEDF, angiostatin, endostatin, tumstatin, canstatin and arresten that have been so far evaluated for regulation of CNV have not only shown promising evidence of CNV regulation, but also provided new strategies for inhibiting CNV through differential mode of actions. Such variation exhibited by different endogenous angioinhibitors can be beneficial in targeting CNV using different combinations of these inhibitors. It can be
realized that these naturally occurring inhibitors can pose low immune reactions and thus, an efficient way of regulating diseases. Further, clinical studies using individual and combinations of endogenous angioinhibitors, included in different regimens along with current therapies of CNV would elaborate the application of endogenous angioinhibitors for regulating CNV of AMD.

4. Acknowledgements

This study was supported by Flight Attendant Medical Research Institute Young Clinical Scientist Award Grant FAMRI-062558, NIH/NCI Grant RO1CA143128, Dobleman Head and Neck Cancer Institute Grant DHNCI-61905 and startup research funds of Cell Signaling, Retinal and Tumor Angiogenesis Laboratory at Boys Town National Research Hospital to YAS.

5. References


Regulation of Angiogenesis in Choroidal Neovascularization of Age Related Macular Degeneration by Endogenous Angiostatin


This book focuses on the different aspects of ophthalmology - the medical science of diagnosis and treatment of eye disorders. Ophthalmology is divided into various clinical subspecialties, such as cornea, cataract, glaucoma, uveitis, retina, neuro-ophthalmology, pediatric ophthalmology, oncology, pathology, and oculoplastics. This book incorporates new developments as well as future perspectives in ophthalmology and is a balanced product between covering a wide range of diseases and expedited publication. It is intended to be the appetizer for other books to follow. Ophthalmologists, researchers, specialists, trainees, and general practitioners with an interest in ophthalmology will find this book interesting and useful.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: